ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 Molecular Partners AG , a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs
Wall Street Breakfast: The Week Ahead seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose